These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 25773479)

  • 1. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
    Rasool MF; Khalil F; Läer S
    Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalil F; Läer S
    Drug Metab Dispos; 2016 Jul; 44(7):1103-15. PubMed ID: 27068272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Author's Reply to Zheng et al.: A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows.
    Rasool MF; Khalil F; Läer S
    Clin Pharmacokinet; 2016 Jan; 55(1):139-41. PubMed ID: 26649872
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on: "A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood".
    Li GF; Gu X; Yu G; Zhao SY; Zheng QS
    Clin Pharmacokinet; 2016 Jan; 55(1):133-7. PubMed ID: 26649873
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.
    Rasool MF; Khalil F; Läer S
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):383-396. PubMed ID: 27313074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.
    Albers S; Meibohm B; Mir TS; Läer S
    Br J Clin Pharmacol; 2008 Apr; 65(4):511-22. PubMed ID: 17995971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
    Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
    Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases.
    Rasool MF; Ali S; Khalid S; Khalid R; Majeed A; Imran I; Saeed H; Usman M; Ali M; Alali AS; AlAsmari AF; Ali N; Asiri AM; Alasmari F; Alqahtani F
    Sci Rep; 2021 Apr; 11(1):8589. PubMed ID: 33883647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug-drug interaction in healthy adults and its extrapolation to virtual chronic heart failure patients for dose optimization.
    Rasool MF; Läer S
    Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):717-724. PubMed ID: 33910429
    [No Abstract]   [Full Text] [Related]  

  • 10. Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters.
    Läer S; Mir TS; Behn F; Eiselt M; Scholz H; Venzke A; Meibohm B; Weil J
    Am Heart J; 2002 May; 143(5):916-22. PubMed ID: 12040358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CLINICAL EFFICACY OF THE RECEPTOR BETA AND ALPHA BLOCKERS - CARVEDILOL AND ORNITHINE-ASPARTATE IN PATIENTS WITH CHD AND CHF COMBINED WITH ALCOHOLIC LIVER DISEASE].
    Evdokimova AG; Tomova AV; Tereshchenko OI; Zhukolenko LV; Evdokimov VV
    Eksp Klin Gastroenterol; 2016; (6):42-7. PubMed ID: 30280552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
    Heitmann M; Davidsen U; Stokholm KH; Rasmussen K; Burchardt H; Petersen EB
    Scand J Clin Lab Invest; 2002; 62(2):97-104. PubMed ID: 12004934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure.
    Tenero D; Boike S; Boyle D; Ilson B; Fesniak HF; Brozena S; Jorkasky D
    J Clin Pharmacol; 2000 Aug; 40(8):844-53. PubMed ID: 10934668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure.
    Krämer BK; Ress KM; Erley CM; Risler T
    Eur J Clin Pharmacol; 1992; 43(1):85-8. PubMed ID: 1505616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.
    Björkman S
    Br J Clin Pharmacol; 2005 Jun; 59(6):691-704. PubMed ID: 15948934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
    Horiuchi I; Nozawa T; Fujii N; Inoue H; Honda M; Shimizu T; Taguchi M; Hashimoto Y
    Biol Pharm Bull; 2008 May; 31(5):976-80. PubMed ID: 18451529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
    Khalil F; Läer S
    AAPS J; 2014 Mar; 16(2):226-39. PubMed ID: 24399240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products.
    Ibarra M; Valiante C; Sopeña P; Schiavo A; Lorier M; Vázquez M; Fagiolino P
    Eur J Pharm Sci; 2018 Jun; 118():176-182. PubMed ID: 29605455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.